Designer Glycopeptides for Cytotoxic T Cell-based Immunotherapy of Carcinomas
UCSD researchers have demonstrated that human carbohydrate-specific cytotoxic T cells can be generated by immunizing in vitro. In addition, they have tested and shown that the glycopeptides can break immunological tolerance in wild type mice with well-established tumors that express the carbohydrate antigen. Characterization of Tn-specific CTL clones. Dose–response relationship of five representative anti-Tn CTL clones to AIIA(GalNAc-O-S)FAAL measured in a classical 51Cr release assay at a 2:1 E : T ratio. In vitro killing of the syngeneic mammary tumor cell line MMT and themelanoma cells transfected with MUC1 and B16/MUC1, by anti-Tn specific CTL clones measured at a 20:1 E : T ratio. (), 1A7;( ), 3B9; (), 1B3; (), 4E5; (), 1C8.From Ref (2) below.
Patent Number: US20110045046A1
Application Number: US2010918155A
Inventor: Franco, Alessandra
Priority Date: 26 Feb 2008
Priority Number: US20110045046A1
Application Date: 10 Nov 2010
Publication Date: 24 Feb 2011
IPC Current: A61K0009127 | A61K000900 | A61K000914 | A61K003814 | A61K003900 | A61P003500 | A61P003704 | C07K000900 | C12N00050783
US Class: 424422 | 4241851 | 424450 | 435325 | 5140193 | 5140214 | 5140215 | 5140216 | 5140217 | 530322
Assignee Applicant: The Regents of the University of California
Title: GLYCOPEPTIDES AND METHODS OF MAKING AND USING THEM
Usefulness: GLYCOPEPTIDES AND METHODS OF MAKING AND USING THEM
Summary: (I) is useful in a composition, which is formulated as a vaccine for treating, preventing or ameliorating a disease or condition associated with a dysfunctional cell or a cancer or a tumor cell, for treating, preventing or ameliorating cancer or a tumor, or to prevent, decrease the amount of or ameliorate metastasis a cancer or a tumor, where the cancer is e.g. epithelial origin, a lymphoma, Hodgkin's disease, a chronic or acute leukemia, a lymphocytic lymphoma leukemia, a neoplasm of CNS, a primary CNS lymphoma, a spinal axis tumor, a brain stem glioma, a pituitary adenoma or a cutaneous or systemic melanoma. (I) is useful: to generate (elicit) an antigen-specific cytotoxic lymphocyte response and/or an antigen-specific helper T cell response, and/or a cluster of differentiation (CD)8+ or a CD4+ T cell response; and for lowering prostate serum antigen serum levels in an individual and for inducing (eliciting) an anti-tumor antigen antibody humoral B cell response (all claimed).
Novelty: New isolated glycopeptide (glycoconjugate) comprising e.g. at least one carbohydrate moiety conjugated (linked) to tumor-associated antigen-derived peptide, is vaccine useful to treat e.g. carcinoma, lymphoma and Hodgkin's disease
Disease Diagnostic/Treatment
Cancer/Tumor
9156906
Related Materials Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions; Franco A. Anticancer Agents Med Chem 2008 Jan; 8(1) 86-91 Review. PMID 18220508 Tech ID/UC Case 23024/2008-189-0 Related Cases 2008-189-0
Tumor associated carbohydrate antigens: a possible avenue for cancer prevention. Franco et al; Immunol Cell Biol., 2005 Aug; 83(4) 440-8 PMID 16033540
CTL-based cancer preventive/therapeutic vaccines for carcinomas; role of tumor associated carbohydrate antigens. Franco A.; Scand J Immunol. 2005 May; 61 (5): 391-7 Review. PMID 15882430
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. Franco et al. J Exp Med. 2004 Mar 1; 199(5); 707-16 PMID 14993254
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. Franco et al. J Exp Med. 2004 Mar 1; 199(5); 707-16 PMID 14993254
USA
